Jpmorgan Chase & CO Arbutus Biopharma Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
138Shares Held
95.4MCall Options Held
3.44MPut Options Held
377K-
Morgan Stanley New York, NY21MShares$81.1 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$49.8 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$44.7 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$33.2 Million10.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.02MShares$27.2 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $580M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...